Group 1 - The core viewpoint of the article highlights that Hengan International's stock has increased by over 3%, reaching HKD 25, with a trading volume of HKD 135 million [1] - For the six months ending June 30, 2025, Hengan International reported a revenue of RMB 11.808 billion, a slight decrease of 0.2% year-on-year [1] - The profit attributable to equity holders was RMB 1.373 billion, reflecting a year-on-year decrease of 2.6% [1] Group 2 - The company maintained an interim dividend of RMB 0.7 per share [1] - Hengan International expects steady growth in tissue sales in the second half of 2025, which will support overall revenue [1] - The company anticipates stable revenue due to strategies focused on multi-channel sales, product personalization, and stable pricing [1] Group 3 - In the second half of 2025, Hengan International plans to increase marketing resource allocation, expecting a positive impact on sales [1] - High-end, high-margin products are projected to continue stable growth [1] - The company expects gross margins to remain stable, assuming raw material prices remain steady [1]
恒安国际午后涨超3% 上半年纯利同比跌2.6% 中期息维持0.7元